Pay in 4 interest-free payments of $6.90 Learn more
Ships within 48 hours · Estimated delivery Oct 19 - Oct 24
Wait 24-48 hours
Trial in progress: Phase 1 study of BI 1823911, an irreversible KRASG12C inhibitor targeting KRAS in its GDP-loaded state, as monotherapy and in combination with the pan-KRAS SOS1 inhibitor BI 1701963 in solid tumors expressing KRASG12C mutation
This premium quality cream combines gentle exfoliation with powerful whitening and brightening agents to reveal a radiant complexion
Psychiatry 10 , 265 (2020)
US$ 28.26
US$ 21.24
US$ 20.23
US$ 26.89
